Start with purpose
Made with intention
Define what the formula should do and how the delivery system should support it.
Beyond the label
Not Just Liposomal.
We believe “liposomal” should mean more than a word on the label. It should mean a formula made with intention, examined with purpose and explained with clarity.
From our Korean development platform to your daily routine, Haroutine is helping lead a more accountable standard for liposomal nutrition.
Evidence is specific to the tested ingredient, formula version and study conditions. Not every formula has completed every optional performance stage.
Why validation matters
The label is only the beginning.
Two products can both say “liposomal” and be made very differently. Validation helps us look beyond the word—to understand what was made, how it holds up and how far the evidence really goes.
Choose the right method
Looked at closely
Use different tools to examine structure, consistency, stability and performance.
Make the proof useful
Shared with clarity
Connect every result to the exact sample, formula and limitation that give it meaning.
That is what “validated” should mean: not one badge, but a more intentional process.
The Korean platform
Leading with validation from South Korea.
Haroutine is backed by Wooree’s connected Korean development and manufacturing platform—bringing formulation, production and structural imaging closer together.
For us, leadership means looking closer, asking better questions and being clear about what each result can actually show.
See the Cryo-TEM process
How we validate
Four questions. One intentional process.
Instead of hiding behind technical language, our process follows four practical questions—from verifying the formula to studying what happens in people.
Is the formula what it says it is?
Confirm identity, active amounts, purity, composition, relevant contaminants and finished-batch release.
Was the liposomal system actually formed?
Examine visible structure, the broader particle population and how much active is associated with the carrier.
Does it remain consistent?
Connect manufacturing controls with stability testing and, when useful, modeled digestive conditions.
What happens in people?
Human pharmacokinetic research measures exposure for one defined preparation. Human outcomes require a separate study.
Additional Haroutine formula-specific PK studies are planned.
Where we are today
A human PK study has been completed for a Wooree-supplied liposomal vitamin C preparation. Additional ingredient- and formula-specific PK studies are planned. Until then, one ingredient’s result is not used as proof for another.
For those who want the details
Six ways we look closer.
No single test tells the whole story. Each method answers a different question—and helps keep the meaning of the result clear.
01StructureMorphology
Did vesicular structures form?
Method Cryogenic transmission electron microscopy (Cryo-TEM)
Can establishVisible morphology, shape, lamellarity and approximate dimensions in the imaged fields.
Cannot establish aloneEncapsulation percentage, shelf life, human absorption or clinical benefit.
02StructureParticle population
What does the broader particle population look like?
Methods Dynamic light scattering (DLS), polydispersity index (PDI) and, when appropriate, nanoparticle tracking analysis (NTA)
Can establishHydrodynamic size and distribution under the stated measurement conditions.
Cannot establish aloneThat every measured particle is a bilayer vesicle carrying the active.
03StructureActive association
How much active is associated with the carrier?
Method Separate free or unassociated active, then use an ingredient-specific quantitative assay with recovery controls.
Can establishMeasured encapsulation or association for the tested sample and defined calculation.
Cannot establish aloneDigestive survival, increased exposure or a health outcome.
04IntegrityProcess & stability
Can the process reproduce the system—and does it remain within specification?
Methods In-process controls, multi-lot trending, accelerated studies and real-time stability in the intended package.
Can establishConsistency and change in potency, particle properties, appearance and other defined attributes.
Cannot establish aloneHuman absorption or a health benefit. Accelerated data is not completed real-time shelf-life evidence.
05IntegrityDigestive behavior
How does the formula behave under modeled digestive conditions?
Method A defined oral, gastric and intestinal model with a prespecified measurement and suitable controls.
Can establishWhat changed in the stated laboratory model.
Cannot establish aloneWhat happens in a person, how much active is absorbed or whether a benefit follows.
06PerformanceHuman exposure
Does the tested preparation change measured exposure in people?
Method A human pharmacokinetic study using a defined formula, dose, population and comparator.
Can establishDifferences in prespecified measures such as concentration and exposure over time.
Cannot establish aloneA clinically meaningful health outcome—or results for a different formula.
Inside the Cryo-TEM process
See what “liposomal” looks like.
Cryo-TEM freezes a hydrated sample extremely quickly, helping preserve delicate structures for direct imaging. It gives the team a way to look for visible vesicles instead of relying on the label alone.
What the image can show
Visible shape, lamellarity, aggregation and approximate dimensions in the selected fields.
Where the claim stops
A micrograph does not measure the amount of active encapsulated, shelf-life stability, absorption or clinical effectiveness.
What each step tells us
One result cannot tell the whole story.
Each step adds a different piece of the picture. Haroutine keeps those pieces connected—without asking one result to prove more than it can.
See it
Was the delivery system formed?
Visible structure, size distribution and active association.
Follow it
Does it remain consistent?
Process consistency, stability and modeled digestive behavior.
Study it
Does it change exposure?
Human pharmacokinetic measures under defined study conditions.
Understand it
Does it change an outcome?
Product-specific human outcomes in the studied population.
Seeing it is not the same as proving absorption. Measuring exposure is not the same as proving a benefit.
Human research
The science is promising. The formula still matters.
Human studies show that liposomal delivery can change exposure for some specific preparations. They also show why no result should be treated as universal across every nutrient or formula.
Most relevantHaroutine formula
Evidence tied to the current retail formula and version.
Platform contextWooree platform
Evidence for an identified ingredient or preparation developed by the platform.
Scientific contextExternal research
Evidence that explains a method or category—never relabeled as Haroutine proof.
Vitamin C · 27-adult crossover study
A randomized, double-blind crossover study reported higher plasma and leukocyte exposure for one proprietary liposomal vitamin C preparation versus standard vitamin C.
Limit: The result belongs to the specific preparation studied. It is not a Haroutine product result and does not establish a health outcome.
Read the studyMinerals · 25-adult study
A nutrient-matched crossover study found larger iron changes at selected timepoints with the tested liposomal multivitamin, while magnesium exposure measures did not differ.
Why it matters: Delivery results can differ by nutrient—even inside the same product. That is exactly why each question should be tested.
Read the studyGlutathione · 12-adult study
A one-month pilot reported increases from baseline in glutathione levels across several blood compartments after daily use of the tested liposomal preparation.
Limit: The study was small and did not include a placebo or non-liposomal comparison group.
Read the studyCoQ10 · comparative absorption study
A double-blind, placebo-controlled randomized trial reported higher absorption for one proprietary liposomal CoQ10 preparation.
Limit: This finding is specific to the preparation studied. It is not proof for Haroutine NMN, CoQ10 or any other formula.
Read the study
Haroutine research roadmap
Vitamin C completed. More formula-specific PK ahead.
Our current human PK evidence is limited to a Wooree-supplied liposomal vitamin C preparation. Additional ingredient- and formula-specific PK studies are planned.
What transparency looks like
A result without context is only half the story.
Every published evidence record should make the sample and the claim boundary easy to inspect.
- 01Product and formula version
- 02Material or lot tested
- 03Question and validation stage
- 04Method and test conditions
- 05Result and acceptance criterion
- 06Plain-language meaning
- 07Explicit limitation
- 08Report date and next review
An applicable approved specification was tested and passed.
A defined study or characterization is complete and the result is available.
A protocol is active. No positive result is implied.
The stage has not been completed for this formula.
Questions, answered
What “validated” really means.
Short answer: it should tell you what was tested, how it was tested and how far the result goes.
Does liposomal automatically mean better absorbed?
No. “Liposomal” describes an intended delivery design. Improved human exposure requires a relevant pharmacokinetic study of the identified preparation, dose and comparator.
What does Cryo-TEM show?
Cryo-TEM can provide direct images of hydrated vesicular structures, including visible shape and lamellarity. It does not measure encapsulation, stability, absorption or a health outcome by itself.
Why use more than one method?
Each method answers a different question. Imaging examines visible morphology; particle analysis characterizes a population; ingredient assays quantify active; stability tracks change; human research measures people.
Does smaller particle size mean better?
Not automatically. A useful size range is formula- and purpose-specific. Size alone does not establish bilayer structure, active loading, stability or superior absorption.
Is encapsulation efficiency the label amount?
No. Label amount describes the quantity of an ingredient per serving. Encapsulation or association describes the fraction measured with the carrier under a defined analytical method.
Does a digestive model prove what happens in my body?
No. A digestive model can reveal how a formula behaves under controlled laboratory conditions. Human digestion, absorption and health outcomes require different studies.
Do you have human clinical research?
A human PK study has been completed for a Wooree-supplied liposomal vitamin C preparation. Additional ingredient- and formula-specific PK studies are planned. External liposome research is presented as category context—not as proof for a Haroutine formula that was not studied.
Choose with clarity
Look beyond the label.
Choose liposomal formulas backed by clearer questions, more intentional evaluation and evidence that stays connected to the formula it belongs to.
Scientific and regulatory references
- 21 CFR Part 111 — Current Good Manufacturing Practice for Dietary Supplements
- FDA — Liposome Drug Products: CMC and Human Pharmacokinetics (technical context for drug products; not an FDA supplement standard)
- FTC — Health Products Compliance Guidance
- Brodkorb et al., 2019 — INFOGEST static in vitro digestion method
- Davis et al., 2016 — Liposomal-encapsulated ascorbic acid pharmacokinetics
- Purpura et al., 2024 — Liposomal vitamin C plasma and leukocyte pharmacokinetics
- Tinsley et al., 2022 — Liposomal mineral absorption randomized crossover trial
- Sinha et al., 2018 — Oral liposomal glutathione pilot study
- Jäger et al., 2025 — Liposomal CoQ10 absorption randomized trial